Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model

OncoImmunology

Volumn 6, Issue 8, 2017, Pages

  Nestvold, Janne ^a   Wang, Meng Yu ^a   Camilio, Ketil A ^a,b   Zinöcker, Severin ^c   Tjelle, Torunn Elisabeth ^c   Lindberg, Alf ^b   Haug, Bengt Erik ^d   Kvalheim, Gunnar ^a   Sveinbjørnsson, Baldur ^b,e   Rekdal, Øystein ^b,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LYTIX BIOPHARMA AS   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

DAMP; Immunotherapy; LTX 315; oncolytic peptide; Sarcoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CISPLATIN; CYTOCHROME C; DACARBAZINE; DANGER ASSOCIATED MOLECULAR PATTERN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; PEPTIDE LTX 315; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; EXPERIMENTAL SARCOMA; FIBROSARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; RAT; SPLEEN CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

EID: 85027837205     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1338236     Document Type: Article

References (38)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415(6870):389-95; PMID:11807545; https://doi.org/10.1038/415389a
2. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes 1999; 1462(1–2):55-70; https://doi.org/10.1016/S0005-2736(99)00200-X
3. Gaspar D, Veiga AS, Castanho MARB. From antimicrobial to anticancer peptides. A review. Frontiers in Microbiology 2013; 4:294; https://doi.org/10.3389/fmicb.2013.00294
4. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009; 625(1–3):190-4; PMID:19835863; https://doi.org/10.1016/j.ejphar.2009.08.043
5. Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, et al. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. J Med Chem 2016; 59(7):2918-27; PMID:26982623; https://doi.org/10.1021/acs.jmedchem.5b02025
6. Camilio KA, Rekdal Ø, Sveinbjörnsson B. LTX-315 (Oncopore™):A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology 2014; 3:e29181; PMID:25083333; https://doi.org/10.4161/onci.29181
7. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005; 4(4):612-24; PMID:15827335; https://doi.org/10.1158/1535-7163.MCT-04-0077
8. Eike L-M, Yang N, Rekdal Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget 2015; 6(33):34910-23; PMID:26472184
9. Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, Liu P, Yang H, Bezu L, Müller K, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis 2016; 7(3):e2134; https://doi.org/10.1038/cddis.2016.47
10. Camilio KA, Berge G, Ravuri CS, Rekdal Ø, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunology, Immunotherapy 2014; 63(6):601-13; https://doi.org/10.1007/s00262-014-1540-0
11. Yamazaki T, Pitt JM, Vetizou M, Marabelle A, Flores C, Rekdal O, Kroemer G, Zitvogel L. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ 2016; 23(6):1004-15; PMID:27082453; https://doi.org/10.1038/cdd.2016.35
12. Wang M-Y, Nestvold J, Rekdal Ø, Kvalheim G, Fodstad Ø. A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties. Exp Cell Res 2017; 352(2):218-24; PMID:28189639; https://doi.org/10.1016/j.yexcr.2017.02.005
13. Kim Y, Joo KM, Jin J, Nam D-H. Cancer Stem Cells and Their Mechanism of Chemo-Radiation Resistance. Int J Stem Cells 2009; 2(2):109-14; PMID:24855529; https://doi.org/10.15283/ijsc.2009.2.2.109
14. Shang B, Liu Y, Jiang S-j, Liu Y. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers:A systematic review and meta-analysis. Sci Rep 2015; 5:15179; PMID:26462617; https://doi.org/10.1038/srep15179
15. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer:A systematic review with meta-analysis. Br J Cancer 2011; 105(1):93-103; PMID:21629244; https://doi.org/10.1038/bjc.2011.189
16. Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, Wicha MS. Targeting cancer stem cells using immunologic approaches. Stem cells (Dayton, Ohio) 2015; 33(7):2085-92; PMID:25873269; https://doi.org/10.1002/stem.2039
17. Chen K, Huang Y-h, Chen J-l. Understanding and targeting cancer stem cells:Therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34(6):732-40; PMID:23685952; https://doi.org/10.1038/aps.2013.27
18. Harris F, Dennison SR, Singh J, Phoenix DA. On the selectivity and efficacy of defense peptides with respect to cancer cells. Med Res Rev 2013; 33(1):190-234; PMID:21922503; https://doi.org/10.1002/med.20252
19. Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S, Müller K, Liu P, Zitvogel L, Rekdal Ø, et al. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget 2015; 6(29):26599-614; PMID:26378049; https://doi.org/10.18632/oncotarget.5613
20. Mole RH. Whole Body Irradiation—Radiobiology or Medicine? Br J Radiol 1953; 26(305):234-41; PMID:13042090; https://doi.org/10.1259/0007-1285-26-305-234
21. Levy A, Chargari C, Marabelle A, Perfettini J-L, Magné N, Deutsch E. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur J Cancer 2016; 62:36-45; https://doi.org/10.1016/j.ejca.2016.03.067
22. Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer 2016; 4:29; https://doi.org/10.1186/s40425-016-0133-1
23. Forveille S, Zhou H, Sauvat A, Bezu L, Müller K, Liu P, Zitvogel L, Pierron G, Rekdal Ø, Kepp O, et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle 2015; 14(21):3506-12; PMID:26566869; https://doi.org/10.1080/15384101.2015.1093710
24. Sistigu A, Manic G, Vitale I. LTX-315, CAPtivating immunity with necrosis. Cell Cycle 2016; 15(9):1176-7; PMID:26986689; https://doi.org/10.1080/15384101.2016.1160609
25. Voo KS, Zeng G, Mu J-B, Zhou J, Su X-Z, Wang R-F. CD4+ T-Cell Response to Mitochondrial Cytochrome in Human Melanoma. Cancer Res 2006; 66(11):5919-26; PMID:16740732; https://doi.org/10.1158/0008-5472.CAN-05-4574
26. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3(9):e955691; PMID:25941621; https://doi.org/10.4161/21624011.2014.955691
27. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17(2):97-111; PMID:27748397; https://doi.org/10.1038/nri.2016.107
28. Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy:Targeting the tumor microenvironment. J Transl Med 2012; 10(1):70; PMID:22490302; https://doi.org/10.1186/1479-5876-10-70
29. Friedl P, Alexander S. Cancer invasion and the microenvironment:Plasticity and reciprocity. Cell. 2011 Nov 23; 147(5):992-1009; doi:10.1016/j.cell.2011.11.016
30. Broussard EK, Disis ML. TNM Staging in Colorectal Cancer:T Is for T Cell and M Is for Memory. J Clin Oncology 2011; 29(6):601-3; https://doi.org/10.1200/JCO.2010.32.9078
31. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathology 2014; 232(2):199-209; PMID:24122236; https://doi.org/10.1002/path.4287
32. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours:Impact on clinical outcome. Nat Rev Cancer 2012; 12(4):298-306; PMID:22419253; https://doi.org/10.1038/nrc3245
33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 2006; 313(5795):1960-4; PMID:17008531; https://doi.org/10.1126/science.1129139
34. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515(7528):568-71; PMID:25428505; https://doi.org/10.1038/nature13954
35. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:22437870; https://doi.org/10.1038/nrc3239
36. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14(10):1014-22; PMID:24048123; https://doi.org/10.1038/ni.2703
37. Nestvold J, Stokland A, Naper C, Rolstad B. Phenotype and Natural Killer Cell Sensitivity of a Radiation-Induced Acute T-Cell Leukaemia (Roser Leukaemia) in PVG Rats. Scand J Immunol 2004; 60(1–2):153-8; PMID:15238084; https://doi.org/10.1111/j.0300-9475.2004.01436.x
38. Mosmann T. Rapid colorimetric assay for cellular growth and survival:Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1):55-63; PMID:6606682; https://doi.org/10.1016/0022-1759(83)90303-4